Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.


TICSI evaluated whether AZD4017, an 11ß-HSD1 inhibitor, could reduce glucocorticoid-associated side effects on blood pressure, blood glucose levels, bone, and lipid metabolism in healthy men.


Randomised, double-blind, placebo-controlled trial comparing the effects of AZD4017 with a placebo (dummy pill), when administered together with prednisolone (a glucocorticoid) for 7 days.


32 participants were randomised; 30 completed the trial per protocol and were included in the analysis.

The primary endpoint of the study (change in glucose disposal during a two-step hyperinsulinaemic, normoglycaemic clamp) was not met. Over a 7-day period, investigators showed that AZD4017 significantly improved the adverse effects of prednisolone on levels of blood glucose and lipids, bone health, and blood pressure compared with placebo. Importantly, many of the desirable, anti-inflammatory actions of prednisolone were retained.

In conclusion, co-administration of AZD4017 with prednisolone in men is a potential strategy to limit its adverse glucocorticoid effects.

The full published article can be viewed here.


Chief investigator Jeremy Tomlinson
Co-investigator Rury Holman
Sponsor University of Oxford
Funder Medical Research Council (MRC)
Reference number NCT03111810